NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Common antibody test can be adapted for COVID-19, study finds

Common antibody test can be adapted for COVID-19, study finds

20 April 2020 · Listed under COVID-19, Inflammation across Tissues, Modernising Medical Microbiology and Big Infection Diagnostics

Research led from Oxford has found that an immunological assay commonly used to measure antibodies, antigens and proteins in biological samples can be specifically adapted to detect and quantifying COVID-19 antibodies.

The investigations by the National COVID Testing Scientific Advisory Panel were co-ordinated by Prof Derrick Crook at the University of Oxford. The trial involved researchers at Oxford University Hospitals NHS Foundation Trust, NHS Blood and Transplant, and ISARIC CCP-UK, University of Liverpool. Funding was provided by the NIHR Oxford Biomedical Research Centre (BRC), Wellcome Trust, MRC and the Department of Health and Social Care

They found that an enzyme-linked immunosorbent assay (ELISA) could be calibrated to be specific for detecting and quantifying SARS-CoV-2 (COVID-19) IgM and IgG immunoglobulin, and was highly sensitive for IgG immunoglobulin from 10 days following the onset of symptoms.

The study, published as a pre-print on medRxiv, also found that the performance of current lateral flow immunoassay (LFIA) devices was inadequate for most individual patient applications.

Prof Crook said: “There is an urgent need for robust and reliable antibody detection approaches to support diagnostics, the development of vaccines and the ability of people to leave quarantine safely.

“There has been considerable interest in LFIA devices – which work like pregnancy tests – but our study has found that these kits are not sensitive or specific enough, and their overall performance makes them unsuitable for testing individuals.”

The research team used a panel of plasma samples designated SARS-CoV-2 positive and negative and tested them for SARS-Cov-2 IgM and IgG antibodies using ELISA and nine different commercially available LFIA devices.

Gavin Screaton, Head of the University of Oxford’s Medical Sciences Division, said: “This has been a fantastic collaborative effort by a large national consortium of researchers.

“The novel in-house ELISA test has performed very well in these trials, and provides a clear way forward for the development of commercial high-throughput antibody testing.

← Oxford-led research describes the safety profile and potential harms of hydroxychloroquine and azithromycin
BRC funds three further COVID-19 studies →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre